<DOC>
	<DOCNO>NCT02273050</DOCNO>
	<brief_summary>A Multicenter , Randomized , Double-Blind , Active-Controlled , Phase 3 Trial Evaluate Efficacy Safety Saxagliptin Combination Metformin IR Initial Therapy Compared Saxagliptin Monotherapy Metformin IR Monotherapy Subjects Type 2 Diabetes Inadequate Glycaemic Control</brief_summary>
	<brief_title>Evaluate Efficacy Safety Saxagliptin Combination With Metformin IR Compared Saxagliptin Monotherapy Metformin IR Monotherapy Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control</brief_title>
	<detailed_description>Allocation : Randomized Endpoint Classification : Efficacy/Safety study Intervention Model : Parallel Assignment Masking : Double Blind Primary Purpose : Treatment</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Subjects type 2 diabetes mellitus ; 2 . HbA1c ≥8 % ≤12 % ; 3.Fasting Cpeptide ≥1.0 ng/ml ; 4 . Subject drug naïve ; 5 . Body mass index ≤40 kg/m2 . 1 . Symptoms poorly control diabetes ; 2 . Chronic repeat intermittent corticosteroid treatment ; 3 . Calculated creatinine clearance &lt; 60 ml/min serum creatinine &gt; 132.6 μmol/L ( &gt; 1.5 mg/dL ) men , &gt; 123.8 μmol/L ( &gt; 1.4 mg/dL ) woman ; 4 . Creatine Kinase ≥3x ULN ; 5.Abnormal TSH value screen evaluate free T4 , subject abnormal free T4 exclude ; 6 . History administration antihyperglycaemic therapy total 28 day three consecutive day total seven nonconsecutive day eight week prior screen ; 7 . Current treatment strong CYP3A4/5 inhibitor ; 8 . Prior treatment saxagliptin DPP4 inhibitor ; 9 . Significant history cardiovascular disease , renal disease , psychiatric disorder , Immunocompromised individual , hemoglobinopathy , liver disease , Pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Type 2 Diabetes Mellitus , Dipeptidyl-Peptidase 4 Inhibitors , Saxagliptin , Metformin , Endocrine System Diseases</keyword>
</DOC>